
Inovio Pharmaceuticals (INO) Stock Forecast & Price Target
Inovio Pharmaceuticals (INO) Analyst Ratings
Bulls say
Inovio Pharmaceuticals is attractive because VOCERYQ’s FDA accelerated approval validates its DNA-medicine platform and converts a long-development story into a near-term commercial opportunity in RRP, a rare disease with meaningful unmet need. Clinical data from the Phase 1/2 RRP-001 study were compelling, with 81% of patients requiring fewer surgeries, 28% achieving complete response, and 2-year results improving to 50% complete response, supporting a differentiated profile versus surgery-heavy care and aiding adoption. Financially, 3Q26 revenue was $0.3M against a $49.2M net loss, but pro forma cash of about $139.8M after financing and warrant exercises should fund operations into late 4Q27 and support the 1Q27 launch.
Bears say
Inovio Pharmaceuticals is a clinical-stage biotechnology company with a highly speculative business model, because its DNA-encoded medicines are novel and may fail in the clinic despite the promise of its platform and INO-3107 program for HPV-6 and HPV-11-associated RRP. The completed Phase 1/2 trial does not eliminate the risk that INO-3107 may not gain approval in RRP or achieve the sales forecast implied by the company’s strategy, leaving limited visibility into durable commercial success. Fundamentally, the outlook remains negative because INOVIO will likely require additional capital to fund development and operations, a dependence that can dilute shareholders and underscore the financial fragility typical of a pre-revenue biotech.
This aggregate rating is based on analysts' research of Inovio Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Inovio Pharmaceuticals (INO) Analyst Forecast & Price Prediction
Start investing in Inovio Pharmaceuticals (INO)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Inovio Pharmaceuticals (INO) Forecast
Inovio Pharmaceuticals (INO) Analyst Forecast & Price Prediction
Start investing in Inovio Pharmaceuticals (INO)
Order type
Buy in
Order amount
Est. shares
0 shares